Bryan Rudolph1, Nicole Bjorklund2, Nadia Ovchinsky3, Debora Kogan-Liberman3, Adriana Perez3, Mark Liszewski4, Terry L Levin4, Michelle Ewart4, Qiang Liu4, Xiaonan Xue5, Shankar Viswanathan5, Howard D Strickler5. 1. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA. Electronic address: brudolph@montefiore.org. 2. Division of Endocrinology, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY, USA; Institute of Clinical and Translational Research, Albert Einstein College of Medicine, Bronx, NY, USA. 3. Division of Pediatric Gastroenterology, Hepatology and Nutrition, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA. 4. Division of Pediatric Radiology, Children's Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, USA. 5. Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, USA.
Abstract
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is strongly associated with obesity and is the most common liver disease in the developed world. In children with suspected NAFLD, present guidelines suggest consideration of alternative diagnoses via extensive blood testing, though the yield of this work up is unknown. Furthermore, the gold standard diagnostic test for NAFLD remains liver biopsy, making the development of non-invasive tests critically important. OBJECTIVES: Our objectives are: 1) to determine the accuracy of elastography and multiple serum biomarkers - each assessed individually and as algorithms (including those previously tested in adults) - for the diagnosis of nonalcoholic steatohepatitis (NASH) and early fibrosis in children and (2) to examine the utility of extensive testing for rare alternative diagnoses in overweight or obese children with elevated alanine aminotransferase (ALT) suspected to have NAFLD. DESIGN: This is an ongoing, cross-sectional study in children 2-18 years of age with up to 2 years of prospective follow up. Eligible patients are asymptomatic, overweight or obese, and have an ALT ≥35 U/L upon enrollment. Two forms of elastography are obtained serially along with anthropometric data and routine laboratory tests. Elastography and serum biomarkers are also performed immediately prior to any clinically-indicated biopsy. METHODS: Between April 2015 and April 2018, 193 children have been enrolled in this ongoing study and 71 have undergone liver biopsy. Here we carefully report the rationale, methodology, and preliminary data for this study.
BACKGROUND:Nonalcoholic fatty liver disease (NAFLD) is strongly associated with obesity and is the most common liver disease in the developed world. In children with suspected NAFLD, present guidelines suggest consideration of alternative diagnoses via extensive blood testing, though the yield of this work up is unknown. Furthermore, the gold standard diagnostic test for NAFLD remains liver biopsy, making the development of non-invasive tests critically important. OBJECTIVES: Our objectives are: 1) to determine the accuracy of elastography and multiple serum biomarkers - each assessed individually and as algorithms (including those previously tested in adults) - for the diagnosis of nonalcoholic steatohepatitis (NASH) and early fibrosis in children and (2) to examine the utility of extensive testing for rare alternative diagnoses in overweight or obesechildren with elevated alanine aminotransferase (ALT) suspected to have NAFLD. DESIGN: This is an ongoing, cross-sectional study in children 2-18 years of age with up to 2 years of prospective follow up. Eligible patients are asymptomatic, overweight or obese, and have an ALT ≥35 U/L upon enrollment. Two forms of elastography are obtained serially along with anthropometric data and routine laboratory tests. Elastography and serum biomarkers are also performed immediately prior to any clinically-indicated biopsy. METHODS: Between April 2015 and April 2018, 193 children have been enrolled in this ongoing study and 71 have undergone liver biopsy. Here we carefully report the rationale, methodology, and preliminary data for this study.
Authors: Jiayun Shen; Henry Lik-Yuen Chan; Grace Lai-Hung Wong; Paul Cheung-Lung Choi; Anthony Wing-Hung Chan; Hoi-Yun Chan; Angel Mei-Ling Chim; David Ka-Wai Yeung; Francis Ka-Leung Chan; Jean Woo; Jun Yu; Winnie Chiu-Wing Chu; Vincent Wai-Sun Wong Journal: J Hepatol Date: 2012-02-04 Impact factor: 25.083
Authors: Robert Russell Ehrman; Adrienne Nicole Malik; Reid Kenneth Smith; Zeid Kalarikkal; Andrew Huang; Ryan Michael King; Rubin David Green; Brian James O'Neil; Robert Leigh Sherwin Journal: Intern Emerg Med Date: 2021-03-20 Impact factor: 3.397
Authors: Bryan Rudolph; Tyler Selig; Yingjie Li; Nadia Ovchinsky; Debora Kogan-Liberman; Mark C Liszewski; Terry Levin; Michelle Ewart; Qiang Liu; Shankar Viswanathan; Juan Lin; Xiaonan Xue; Robert D Burk; Howard D Strickler Journal: JPGN Rep Date: 2021-05